VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide

BACKGROUND: No data are available on the pharmacogenetics of metronomic chemotherapy in prostate cancer. The aim of this study was to evaluate the association between VEGF-A sequence variants and prostate-specific antigen (PSA) progression, progression-free survival (PFS) and overall survival (OS),...

Descripción completa

Detalles Bibliográficos
Autores principales: Orlandi, P, Fontana, A, Fioravanti, A, Di Desidero, T, Galli, L, Derosa, L, Canu, B, Marconcini, R, Biasco, E, Solini, A, Francia, G, Danesi, R, Falcone, A, Bocci, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749570/
https://www.ncbi.nlm.nih.gov/pubmed/23860526
http://dx.doi.org/10.1038/bjc.2013.398

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749570/
https://www.ncbi.nlm.nih.gov/pubmed/23860526
http://dx.doi.org/10.1038/bjc.2013.398

Ejemplares similares